Accueil>>Signaling Pathways>> Microbiology & Virology>> HIV>>Trovirdine (LY300046)

Trovirdine (LY300046)

Catalog No.GC32124

La trovirdine (LY300046) inhibe la RT du VIH-1 avec une IC50 de 7 nM lors de l'utilisation d'une amorce/matrice hétéropolymérique (oligo-ADN/ARN ribosomal) et de dGTP comme substrat.

Products are for research use only. Not for human use. We do not sell to patients.

Trovirdine (LY300046) Chemical Structure

Cas No.: 149488-17-5

Taille Prix Stock Qté
5 mg
63,00 $US
En stock
10 mg
108,00 $US
En stock
25 mg
225,00 $US
En stock
50 mg
405,00 $US
En stock
100 mg
675,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate.IC50 value: 7 nMTarget: HIV-1Trovirdine is currently in phase I clinical trials for potential use in thetreatment of AIDS.

[1]. Zhang, H. et al. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethylthiazolyl thiourea derivatives trovirdine and MSC-127. [2]. Cantrell, A.S. et al. Phenethylthiazolylthiourea (PETT) compounds as a newclass of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.

Avis

Review for Trovirdine (LY300046)

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Trovirdine (LY300046)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.